<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25363" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Multiple Sclerosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tafti</surname>
            <given-names>Dawood</given-names>
          </name>
          <aff>Brooke Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ehsan</surname>
            <given-names>Moavia</given-names>
          </name>
          <aff>Allama Iqbal Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Xixis</surname>
            <given-names>Kathryn L.</given-names>
          </name>
          <aff>East Tennessee State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dawood Tafti declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Moavia Ehsan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kathryn Xixis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25363.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system and is characterized by inflammation, demyelination, gliosis, and neuronal loss.&#x000a0;This condition&#x000a0;manifests with a wide range of neurological symptoms, such as vision impairment, numbness and tingling, focal weakness, bladder and bowel dysfunction, and cognitive impairment.&#x000a0;Multiple sclerosis has various disease courses, including relapsing-remitting, primary progressive, and secondary progressive. Early diagnosis, typically based on episodes separated in time and space, facilitates the prompt initiation of disease-modifying therapy aimed at reducing relapses and long-term disability, which is crucial for accurately diagnosing multiple sclerosis.</p>
        <p>Treatment goals include decreasing relapses and magnetic resonance imaging activity while minimizing permanent disability and addressing various patient concerns such as bladder and bowel dysfunction, depression, cognitive impairment, fatigue, sexual dysfunction, sleep disturbances, and vertigo.&#x000a0;Effective management of multiple sclerosis requires an interdisciplinary approach and various treatment options, including disease-modifying therapies such as glatiramer acetate, dimethyl fumarate, fingolimod, interferon-beta preparations, natalizumab, and mitoxantrone. This activity emphasizes the crucial role of interprofessional healthcare providers in facilitating early intervention for optimal patient outcomes due to the disease's impact on multiple systems and reduced life expectancy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify early signs and symptoms of multiple sclerosis across various neurological domains.</p></list-item><list-item><p>Screen patients at risk for multiple sclerosis or presenting with suggestive symptoms using appropriate diagnostic tests such as magnetic resonance imaging, evoked potentials, and cerebrospinal fluid analysis.</p></list-item><list-item><p>Select appropriate symptomatic treatments for multiple sclerosis&#x02013;related symptoms, such as spasticity, fatigue, pain, and bladder dysfunction.</p></list-item><list-item><p>Collaborate with other healthcare providers to address comorbidities, such as depression, cognitive impairment, and cardiovascular risk factors, in multiple sclerosis patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25363&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25363">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25363.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system (CNS) and is characterized by inflammation, demyelination, gliosis, and neuronal loss.<xref ref-type="bibr" rid="article-25363.r1">[1]</xref>&#x000a0;This condition&#x000a0;manifests with a wide range of neurological symptoms, such as vision impairment, numbness and tingling, focal weakness, bladder and bowel dysfunction, and cognitive impairment.</p>
        <p>Pathologically, perivascular lymphocytic infiltrate and macrophages lead to the degradation of myelin sheaths surrounding neurons, causing symptoms that vary depending on lesion location. Clinical symptoms characterized by acute relapses typically appear first in young adults, followed by a gradually progressive course leading to permanent disability within 10 to 15 years.<xref ref-type="bibr" rid="article-25363.r2">[2]</xref></p>
        <p>Multiple sclerosis presents various disease courses and is classified into 7 categories, as outlined below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Relapsing-remitting (RR): This initial onset is observed in 70% to 80% of multiple sclerosis patients and is characterized by&#x000a0;the below-mentioned neurological presentation.
<list list-type="bullet"><list-item><p>New or recurrent neurological symptoms that are consistent with&#x000a0;multiple&#x000a0;sclerosis</p></list-item><list-item><p>Symptoms lasting 24 to 48 hours</p></list-item><list-item><p>Symptoms developing over days to weeks</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Primary progressive (PP): This course presents in 15% to 20% of patients and shows a gradual deterioration from onset without relapses.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Secondary progressive (SP): Following an initial relapsing-remitting course, this course is marked by a more gradual neurological decline. Superimposed relapses can occur but are not mandatory.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Progressive-relapsing (PR): This course involves gradual deterioration with superimposed relapses and is seen&#x000a0;in 5% of patients.</p>
          </list-item>
        </list>
        <p>Additionally, the following 3 categories are sometimes considered within the spectrum of multiple sclerosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinically isolated syndrome: This is often classified as a single episode of inflammatory CNS demyelination.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fulminant: This is characterized by severe multiple sclerosis with multiple relapses and rapid progression toward disability.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Benign: This features an overall mild disability course with rare relapses.</p>
          </list-item>
        </list>
        <p>When discussing multiple sclerosis, clinicians commonly focus on the relapsing-remitting course due to its high prevalence among affected patients. Relapses in relapsing-remitting multiple sclerosis often show partial or complete recovery over weeks or months, sometimes without treatment. However, residual symptoms from these relapses, without complete recovery, can accumulate over time and contribute to overall disability. Diagnosis of relapsing-remitting multiple sclerosis typically requires evidence of at least 2 CNS inflammatory events. Although various diagnostic criteria exist for multiple sclerosis, the general principle for diagnosing the relapsing-remitting course involves establishing episodes separated in "time and space."<xref ref-type="bibr" rid="article-25363.r3">[3]</xref>&#x000a0;</p>
        <p>This entails that episodes must be temporally separated and involve distinct locations within the CNS. A prompt diagnosis of multiple sclerosis enables the timely initiation of disease-modifying therapy, leading to effective management.<xref ref-type="bibr" rid="article-25363.r1">[1]</xref> Treatment goals include decreasing relapses and magnetic resonance imaging (MRI) activity while minimizing permanent disability and addressing various patient concerns such as bladder and bowel dysfunction, depression, cognitive impairment, fatigue, sexual dysfunction, sleep disturbances, and vertigo.&#x000a0;</p>
      </sec>
      <sec id="article-25363.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Although the exact etiology of multiple sclerosis is unknown, factors involved in pathogenesis are broadly grouped into 3 categories&#x02014; immune factors, environmental factors, and genetic associations.</p>
        <p>Dysimmunity with an autoimmune attack on the&#x000a0;CNS is the leading hypothesized etiology of multiple&#x000a0;sclerosis. The postulated "outside-in" mechanism involves CD4+ proinflammatory T cells among various proposed mechanisms.<xref ref-type="bibr" rid="article-25363.r4">[4]</xref>&#x000a0;Researchers hypothesize that an unknown antigen triggers and activates Th1 and Th17 cells, leading to their attachment to CNS endothelium, crossing the blood-brain barrier, and subsequently causing an immune attack through cross-reactivity. Conversely, the "inside-out" hypothesis suggests an intrinsic CNS abnormality triggering and resulting in inflammatory-mediated tissue damage.<xref ref-type="bibr" rid="article-25363.r4">[4]</xref></p>
        <p>Environmental factors, such as latitudinal gradients observed in various countries, have been extensively studied.<xref ref-type="bibr" rid="article-25363.r5">[5]</xref> Vitamin D deficiency has been considered a possible etiology for the noted predisposition of populations in higher latitudes to multiple sclerosis.<xref ref-type="bibr" rid="article-25363.r6">[6]</xref>&#x000a0;Certain&#x000a0;infections, including Epstein-Barr virus, may also contribute to the disease.<xref ref-type="bibr" rid="article-25363.r7">[7]</xref>&#x000a0;Complex interactions between various environmental factors and patient genetics are apparent, and ongoing research aims to understand these pathways more comprehensively.</p>
        <p>Patients with biological relatives with multiple sclerosis have a heightened risk of developing the condition.<xref ref-type="bibr" rid="article-25363.r8">[8]</xref> Having a first-degree relative with multiple&#x000a0;sclerosis&#x000a0;is associated with a 2% to 4% risk of developing multiple&#x000a0;sclerosis&#x000a0;as compared to &#x000a0;0.1% in the general population.<xref ref-type="bibr" rid="article-25363.r9">[9]</xref> Concordance rates are higher in monozygotic twins (20% to 30%) compared to dizygotic twins (5%).<xref ref-type="bibr" rid="article-25363.r10">[10]</xref>&#x000a0;A 2% concordance exists between parents and children, which is still 10- to 20-fold higher risk than in the general population.<xref ref-type="bibr" rid="article-25363.r11">[11]</xref>&#x000a0;</p>
        <p>The human leukocyte antigen (HLA) DRB1*1501 allele strongly correlates with multiple sclerosis and is one of the most studied alleles relative to multiple&#x000a0;sclerosis&#x000a0;linkage.<xref ref-type="bibr" rid="article-25363.r12">[12]</xref>&#x000a0;No defined Mendelian form of genetic occurrence is apparent, and implications point to numerous genes.<xref ref-type="bibr" rid="article-25363.r13">[13]</xref></p>
        <p>Polymorphisms in several genes may be associated with a slightly increased risk of multiple&#x000a0;sclerosis, including the following:<xref ref-type="bibr" rid="article-25363.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Immunity-related genes:&#x000a0;<italic toggle="yes">HLA-DR</italic>,&#x000a0;<italic toggle="yes">IL2RA</italic>,&#x000a0;<italic toggle="yes">IL4</italic>,&#x000a0;<italic toggle="yes">IL6</italic>,&#x000a0;<italic toggle="yes">IL12B</italic>,&#x000a0;<italic toggle="yes">IL17R</italic>,&#x000a0;<italic toggle="yes">IRF5</italic>,&#x000a0;<italic toggle="yes">CD24</italic>,&#x000a0;<italic toggle="yes">CD58</italic>, and&#x000a0;<italic toggle="yes">EVI5</italic></p>
          </list-item>
          <list-item>
            <p>Vitamin D metabolism:&#x000a0;<italic toggle="yes">VDR</italic>&#x000a0;and&#x000a0;<italic toggle="yes">CYP27B1</italic></p>
          </list-item>
          <list-item>
            <p>Certain genes in mitochondrial DNA</p>
          </list-item>
          <list-item>
            <p>Fibrinolysis:&#x000a0;<italic toggle="yes">PAI-1</italic></p>
          </list-item>
          <list-item>
            <p>CNS function and repair:&#x000a0;<italic toggle="yes">ApoE</italic>&#x000a0;and&#x000a0;<italic toggle="yes">DPP6</italic></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Multiple sclerosis&#x000a0;is the most common immune-mediated inflammatory demyelinating disease of the CNS. This condition affects approximately 400,000 individuals in the United States and 2.5 million individuals worldwide.<xref ref-type="bibr" rid="article-25363.r15">[15]</xref> The disease is 3-fold more common in females&#x000a0;than in&#x000a0;males.<xref ref-type="bibr" rid="article-25363.r15">[15]</xref> Although onset typically occurs in individuals between the ages of 20&#x000a0;and 40, multiple sclerosis can present at any age, with the mean age of onset being 25 to 29 for relapsing-remitting multiple sclerosis and 39 to 41 for primary progressive multiple sclerosis.<xref ref-type="bibr" rid="article-25363.r16">[16]</xref> Almost 10% of the cases are present before the age of 18.<xref ref-type="bibr" rid="article-25363.r17">[17]</xref>&#x000a0;The overall prevalence is cited as 1 in 1000 for populations of European ancestry.<xref ref-type="bibr" rid="article-25363.r18">[18]</xref>&#x000a0;</p>
        <p>Less is known about the prevalence of multiple sclerosis in non-European populations, with most data indicating lower prevalence in individuals of East Asian and African descent.<xref ref-type="bibr" rid="article-25363.r19">[19]</xref>&#x000a0;However, recent studies have observed a higher prevalence in African-American populations, similar to those with European ancestry.<xref ref-type="bibr" rid="article-25363.r19">[19]</xref>&#x000a0;Multiple&#x000a0;sclerosis demonstrates a prevalence gradient based on latitude, with higher prevalence in northern latitudes of Europe and North America. Additionally, observations have noted variable genetic susceptibility factors among different human subpopulations, apart from latitude, suggesting poorly understood genetic factors interacting with environmental influences.</p>
        <p>Several studies have highlighted that populations migrating to regions with higher multiple sclerosis prevalence during childhood also adopt a higher risk of acquiring multiple sclerosis.<xref ref-type="bibr" rid="article-25363.r20">[20]</xref> However, other studies have raised doubts about this observation.<xref ref-type="bibr" rid="article-25363.r21">[21]</xref> Neither genetic nor external risk factors can solely account for the epidemiological patterns seen in multiple sclerosis. Notably,&#x000a0;multiple sclerosis stands as the leading cause of permanent disability among young adults.<xref ref-type="bibr" rid="article-25363.r16">[16]</xref> One study reported an incidence rate of pediatric-acquired multiple sclerosis at 0.51 per 100,000 person-years.<xref ref-type="bibr" rid="article-25363.r9">[9]</xref></p>
      </sec>
      <sec id="article-25363.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of multiple sclerosis primarily affects the CNS and involves various areas such as the cortical gray matter, periventricular and juxtacortical white matter, optic nerves, spinal cord, cerebellum, and meninges.</p>
        <p>The 2 fundamental processes that constitute general pathological processes observed in multiple&#x000a0;sclerosis patients include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Focal inflammation results in macroscopic plaques and injury to the blood-brain barrier.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neurodegeneration involves&#x000a0;microscopic damage to various components of the CNS, such as axons, neurons, and synapses.</p>
          </list-item>
        </list>
        <p>Together, these&#x000a0;2 primary processes result in macroscopic and microscopic injury. Lesions, called plaques, occur in waves throughout the disease course and result from focal inflammation. Multiple&#x000a0;sclerosis plaques predominantly center around small veins and venules,&#x000a0;displaying sharp margins. The chief components of plaque pathology include myelin loss, edema, and axonal injury. During active plaque inflammation, disruption of the blood-brain barrier corresponds to enhancement observed on MRI scans. As the inflammatory process subsides over time, it leads to the formation of an astrocytic scar&#x000a0;(see <bold>Image.&#x000a0;</bold>Perivascular Plaques in Multiple Sclerosis as seen in MRI).&#x000a0;</p>
        <p>Microscopically, multiple&#x000a0;sclerosis&#x000a0;lesions show mononuclear infiltrates with perivenular cuffing and infiltration surrounding the white matter. Innate immune cells such as monocytes and macrophages stimulate T-cell migration across the blood-brain barrier, resulting in blood-brain barrier injury and systemic immune cell infiltration. Microglia, the primary antigen-presenting cells of the primary CNS, often precede cell entry. This CNS injury triggers cytotoxic activities in microglia, leading to the release of nitric oxide and other superoxide radicals. Inflamed areas with blood-brain barrier breakdown are visible on MRI as gadolinium-enhancing lesions.</p>
        <p>Recently, a greater understanding of the critical role of B cells and antibody production has been recognized in the pathogenesis of multiple&#x000a0;sclerosis.<xref ref-type="bibr" rid="article-25363.r22">[22]</xref> B-cell follicles in the meninges of multiple&#x000a0;sclerosis&#x000a0;patients have been noted,&#x000a0;and they are associated with&#x000a0;early-onset multiple sclerosis.<xref ref-type="bibr" rid="article-25363.r23">[23]</xref>&#x000a0;The pathological events ultimately lead to demyelination, neuroaxonal degeneration, loss of synapses, dying-back oligodendrogliopathy, tissue injury, and astrogliosis.</p>
      </sec>
      <sec id="article-25363.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically, multiple&#x000a0;sclerosis plaques are primarily characterized by inflammation and myelin breakdown.<xref ref-type="bibr" rid="article-25363.r24">[24]</xref> Additional features include neurodegeneration and oligodendrocyte injury. The common histopathological stains used to detect multiple sclerosis, with adjunct immunohistochemistry assisting in diagnosis, include hematoxylin and eosin staining, myelin stains such as Luxol fast blue, monocyte and macrophage markers such as CD68, and axonal and astrocyte stains.</p>
        <p>Active plaques exhibit varying degrees of the following features:</p>
        <list list-type="bullet">
          <list-item>
            <p>Extensive macrophage infiltration</p>
          </list-item>
          <list-item>
            <p>Myelin debris&#x000a0;often found&#x000a0;within macrophages</p>
          </list-item>
          <list-item>
            <p>Presence of major myelin protein, notably in late active plaques</p>
          </list-item>
          <list-item>
            <p>Perivascular inflammatory infiltrates</p>
          </list-item>
          <list-item>
            <p>Presence of lymphocytes, particularly CD8-positive cytotoxic T cells</p>
          </list-item>
          <list-item>
            <p>Plump-shaped and mitotic astrocytes</p>
          </list-item>
          <list-item>
            <p>Variable degrees of oligodendrocyte injury</p>
          </list-item>
          <list-item>
            <p>Activated microglia, particularly evident in the peri-plaque white matter zone</p>
          </list-item>
        </list>
        <p>Chronic plaques are known for their circumscribed demyelinated lesions, and they occur more frequently and exhibit the following features:<xref ref-type="bibr" rid="article-25363.r24">[24]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypocellularity and demyelination</p>
          </list-item>
          <list-item>
            <p>Macrophages laden with myelin</p>
          </list-item>
          <list-item>
            <p>Relatively decreased perivascular inflammation compared to active plaques</p>
          </list-item>
          <list-item>
            <p>Resolving edema</p>
          </list-item>
          <list-item>
            <p>In remyelinated plaques, thinly myelinated axons and axons with newly formed myelin sheaths are apparent.</p>
          </list-item>
          <list-item>
            <p>Presence of oligodendrocyte precursor cells, typically seen in remyelinated plaques</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Multiple sclerosis&#x000a0;presents with a broad range of symptoms reflective of the multifocal lesions of the CNS. The severity and diversity of symptoms are influenced by the burden, location, and extent of tissue injury. Interestingly, symptoms may not always align with MRI evidence of active plaques due to the involvement of repair mechanisms and neural plasticity in tissue injury and recovery processes.</p>
        <p>Typical clinical manifestations noted in patient history include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vision symptoms such as vision loss (either monocular or homonymous), double vision, symptoms relating to optic neuritis, and pain with eye movement&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vestibular symptoms such as vertigo and gait imbalance</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bulbar dysfunction, which manifests as dysarthria and dysphagia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Motor symptoms such as weakness (hemiparesis, monoparesis, or paraparesis), tremors, spasticity, and fatigue&#x000a0;<xref ref-type="bibr" rid="article-25363.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sensory symptoms such as loss of sensation, paresthesias, dysesthesias, and a band-like sensation around the chest or abdomen</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Urinary and bowel symptoms ranging from incontinence, retention, urgency, constipation, diarrhea, and reflux</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cognitive symptoms such as memory impairment, executive function impairment, and difficulty concentrating</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Psychiatric symptoms such as depression and anxiety</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Brainstem symptoms such as facial muscle weakness and/or reduced facial sensations,&#x000a0;diplopia,&#x000a0;oscillopsia (jerking sensation in the visual field)</p>
          </list-item>
        </list>
        <p>Features considered atypical for multiple sclerosis include seizures, steady progression of symptoms, deficits developing rapidly within minutes, onset before age 10 or after 50, rigidity or sustained dystonia, cortical deficits such as apraxia, alexia, aphasia, or neglect, and early onset of dementia.</p>
        <p>The relapsing-remitting course of multiple sclerosis, observed in a majority of patients, is characterized by exacerbation and relapses of neurological symptoms, with stability between episodes.<xref ref-type="bibr" rid="article-25363.r26">[26]</xref> The following features generally characterize the relapsing-remitting course of multiple&#x000a0;sclerosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>New or recurrent neurological symptoms</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Symptoms developing over days and weeks</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Symptoms lasting between 24&#x000a0;and 48 hours</p>
          </list-item>
        </list>
        <p>Symptoms from relapses frequently resolve. However, over time, residual symptoms relating to episodes of exacerbation accrue. This accrual of symptoms, generally after 10 to 15 years, results in long-term disability over time. Neurological manifestations are heterogeneous in severity and degree of recovery. The secondary progressive course is often noted in patients with relapsing-remitting after 10 to 15 years of onset and is characterized by a more gradual worsening of symptoms with continued progression with or without superimposed relapses.<xref ref-type="bibr" rid="article-25363.r27">[27]</xref></p>
        <p>A small subset of patients experience a progressive worsening of disability from the disease's onset, known as the primary progressive course of multiple sclerosis. Clinical manifestations in this course commonly include myelopathy, cognitive symptoms, and visual impairments. Diffuse and chronic symptoms may arise from global brain atrophy and widespread cortical demyelination.&#x000a0;</p>
        <p>The physical examination aligns with evaluating the patient's illness history and includes the aspects mentioned below.</p>
        <p>
<bold>HEENT:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Assessment for optic neuritis, which typically presents as subacute monocular central vision loss, along with pain upon eye movement (see&#x000a0;<bold>Image. </bold>Optic Neuritis as an Indicator of Multiple Sclerosis)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Observation of difficulty in adducting during lateral gaze, indicating internuclear ophthalmoplegia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other conditions, such as nystagmus, diplopia, hearing loss, and facial pain</p>
          </list-item>
        </list>
        <p>
<bold>Neuromuscular/neurological:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Partial transverse myelitis is typically unilateral or bilateral and is characterized by sensory disturbances</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Brainstem symptoms often include diplopia, dysphagia, dysarthria, and ataxia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The Lhermitte sign is often described as a shock-like sensation with neck flexion</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperreflexia, tremors, muscle spasms, and weakness</p>
          </list-item>
        </list>
        <p>
<bold>Genitourinary:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Urinary incontinence/retention with an assessment of residual bladder volume <xref ref-type="bibr" rid="article-25363.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Erectile dysfunction with consideration of a nocturnal penile tumescence stamp test if indicated</p>
          </list-item>
        </list>
        <p>
<bold>Isolated syndromes:</bold>
</p>
        <p>Isolated syndromes may present as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Radiographically isolated syndrome:&#x000a0;MRI brain lesions that are characteristic of&#x000a0;multiple&#x000a0;sclerosis but are found in patients, usually incidentally, but they do not have any symptoms of multiple sclerosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinically isolated syndrome: Isolated symptom that may not&#x000a0;fulfill diagnostic criteria for&#x000a0;multiple&#x000a0;sclerosis but can lead to clinically definite multiple&#x000a0;sclerosis.</p>
          </list-item>
        </list>
        <p>If multiple sclerosis is suspected but the patient does not present with typical symptoms, the symptoms mentioned below&#x000a0;should prompt further inquiry.<xref ref-type="bibr" rid="article-25363.r29">[29]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sleep disorders, including obstructive sleep apnea, nocturia, insomnia, and restless legs</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transient (paroxysmal) neurological events, which typically last for seconds and occur with frequencies ranging from hundreds of times per day to only occasionally, may include:
<list list-type="bullet"><list-item><p>Abnormal or unexplained sensation spreading across the body</p></list-item><list-item><p>Brainstem symptoms such as &#x000a0;blurred vision, diplopia, dysarthria, and vertigo</p></list-item><list-item><p>Motor symptoms such as transient inhibition of motor function, tonic spasms, and ataxia</p></list-item><list-item><p>Gustatory symptoms such as taste hallucination and altered taste</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypothermia or hyperthermia (very rarely)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pulfrich phenomenon (based on a mismatch of visual acuity between eyes)
<list list-type="bullet"><list-item><p>Objects moving in a straight line appear to be in an elliptical orbit</p></list-item><list-item><p>May present with&#x000a0;difficulty crossing roads, pouring liquids, playing ball sports, or feeling cars swerving in direction while driving.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The sense of uselessness or loss of function in hand (known as "useless hand of Oppenheim")</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The Lhermitte phenomenon,&#x000a0;occurring&#x000a0;with less commonly observed triggers, such as limb movements, neck extension, or coughing <xref ref-type="bibr" rid="article-25363.r30">[30]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Red Flags for Alternative Diagnoses</bold>
</p>
        <p>Red flags that should alert the clinician to the possibility of other diagnoses include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperacute presentation (maximal deficit in minutes to hours)</p>
          </list-item>
          <list-item>
            <p>Progressive ataxia or cognitive dysfunction</p>
          </list-item>
          <list-item>
            <p>Family history of any other neurological disease</p>
          </list-item>
          <list-item>
            <p>Encephalopathy</p>
          </list-item>
          <list-item>
            <p>Short-lasting symptoms (minutes to hours)</p>
          </list-item>
          <list-item>
            <p>Rapidly progressive disease</p>
          </list-item>
          <list-item>
            <p>Failure to remit</p>
          </list-item>
          <list-item>
            <p>Leptomeningeal disease</p>
          </list-item>
          <list-item>
            <p>Progressive ataxia</p>
          </list-item>
          <list-item>
            <p>Cognitive dysfunction</p>
          </list-item>
          <list-item>
            <p>Complete or fluctuating ophthalmoplegia</p>
          </list-item>
          <list-item>
            <p>Headache and/or meningismus</p>
          </list-item>
          <list-item>
            <p>Multiple cranial neuropathies or hearing loss</p>
          </list-item>
          <list-item>
            <p>Symptoms of systemic disease such as night sweats, weight loss, and fever</p>
          </list-item>
          <list-item>
            <p>Nonspecific&#x000a0;neurological examination findings and/or neurological symptoms not easily localized to the&#x000a0;CNS (such as isolated fatigue)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Pathognomonic tests do not exist to diagnose multiple&#x000a0;sclerosis. Diagnosis is established by considering the patient's history and physical examination, along with MRI findings, evoked potentials, and cerebrospinal fluid (CSF) or blood studies, while also excluding other causes of the patient's symptoms. Clinically, a diagnosis of multiple sclerosis is supported by evidence of one or more relapses, which can be confirmed through objective clinical evidence of one or more lesions or objective clinical evidence of one lesion with reliable historical evidence of a prior relapse.</p>
        <p>Dissemination in space (DIS) and dissemination in time (DIT) are 2 key criteria for accurately diagnosing multiple sclerosis. DIS is assessed by integrating information from the patient's history and physical examination to determine the location of CNS involvement. MRI and evoked potentials also have vital roles in establishing DIS. DIT is established by charting the disease course with a thorough history and documenting the presence of multiple exacerbations over time.&#x000a0;The 2010 McDonald criteria determined that new lesions can demonstrate DIT on a follow-up MRI compared to a baseline scan.<xref ref-type="bibr" rid="article-25363.r31">[31]</xref></p>
        <p>DIS is established by observing at least a&#x000a0;T2 lesion in 2 of the 4 following CNS sites&#x02014;spinal cord, infratentorial, juxtacortical, and periventricular regions. Revisions in the 2017 McDonald criteria increased the sensitivity of diagnosis by&#x000a0;introducing&#x000a0;oligoclonal bands in the&#x000a0;CSF analysis as a marker for establishing DIT. Symptomatic lesions were also included to establish DIT and DIS, and cortical lesions were used to demonstrate DIS.<xref ref-type="bibr" rid="article-25363.r32">[32]</xref></p>
        <p>Evoked potentials help demonstrate slowed conduction indicative of subclinical involvement. These findings are often asymmetric. MRI, CSF, and blood studies are essential in ruling out other etiologies. When possible, all patients should undergo an MRI. Additionally, specific blood studies such as complete blood count (CBC), thyroid-stimulating hormone (TSH), vitamin B12 levels, erythrocyte sedimentation rate (ESR), and antinuclear antibody (ANA) testing should be performed as part of the diagnostic workup.</p>
        <p>The main characteristics of multiple sclerosis lesions on brain MRI can be outlined as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lesions are T2 hyperintense and T1 isointense or hypointense, also known as black holes (see&#x000a0;<bold>Image.</bold> Sagittal FLAIR MRI Brain Image&#x000a0;Demonstrating Linear Hyperintense Lesions).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lesions are typically oval or patchy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A high predilection for periventricular white matter.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lesions are oriented perpendicular to the ependymal surface, known as Dawson fingers (see&#x000a0;<bold>Image.</bold>&#x000a0;Sagittal&#x000a0;FLAIR Sequence Demonstrating a Hyperintense Lesion on MRI).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Active lesions often exhibit gadolinium enhancement, presenting as diffuse or rim enhancement.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thinning of the corpus callosum and parenchymal atrophy (see&#x000a0;<bold>Image.</bold>&#x000a0;Axial FLAIR Sequence Demonstrating&#x000a0;an&#x000a0;Advanced Lesion Burden on MRI).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The disappearance of a black hole is most likely due to the resolution of edema and remyelination.<xref ref-type="bibr" rid="article-25363.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>Spinal cord lesions typically exhibit the following MRI characteristics:</p>
        <list list-type="bullet">
          <list-item>
            <p>Typically located in the cervical or thoracic cord, often in the dorsolateral region.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Little or no cord swelling observed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lesions are focal, with&#x000a0;clearly circumscribed and delineation on T2-weighted sequences.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Size ranges from 3 mm to less than&#x000a0;2 vertebral segments in length.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Unequivocal hyperintensity on T2-weighted sequences visible in 2 planes (eg, sagittal and axial)</p>
          </list-item>
        </list>
        <p>The classic abnormal CSF findings in multiple sclerosis typically include elevated protein and myelin basic protein levels, occasional leukocytes (mainly mononuclear cells), and increased levels of total immunoglobulin G (IgG), free kappa light chains, and oligoclonal bands.<xref ref-type="bibr" rid="article-25363.r34">[34]</xref></p>
        <p>When clinical, imaging, or laboratory features are atypical of multiple&#x000a0;sclerosis, patients are tested for&#x000a0;aquaporin-4 (AQP4) IgG serum autoantibody and the myelin oligodendrocyte glycoprotein IgG autoantibody (MOG-IgG).</p>
        <table-wrap id="article-25363.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Diagnostic Tests&#x000a0;for Multiple Sclerosis</title>
          </caption>
          <table style="width: 600px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Tests</bold>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Percentage of Patients with Abnormal Test Results</bold>
</td>
              </tr>
              <tr style="height: 13.6px;">
                <td style="height: 13.6px;" rowspan="1" colspan="1">Brain MRI</td>
                <td style="height: 13.6px;" rowspan="1" colspan="1">70% - 95%</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Somatosensory evoked potentials</td>
                <td style="height: 13px;" rowspan="1" colspan="1">50%</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Visual evoked responses</td>
                <td style="height: 13px;" rowspan="1" colspan="1">50% - 90%</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Brainstem auditory evoked responses</td>
                <td style="height: 13px;" rowspan="1" colspan="1">20% - 55%</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Cerebrospinal fluid IgG index</td>
                <td style="height: 13px;" rowspan="1" colspan="1">75%</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Cerebrospinal fluid oligoclonal banding</td>
                <td style="height: 13px;" rowspan="1" colspan="1">85%&#x000a0;- 95%</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Table reference is&#x000a0;<xref ref-type="bibr" rid="article-25363.r34">[34]</xref>.</p>
      </sec>
      <sec id="article-25363.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Glatiramer acetate, dimethyl fumarate, fingolimod, interferon-beta preparations, natalizumab, and mitoxantrone are some of the primary disease-modifying therapies. Immediate treatment initiation upon diagnosis is crucial for multiple sclerosis. Short-term goals focus&#x000a0;on decreasing MRI lesion activity, while long-term goals aim to prevent secondary progressive multiple sclerosis. Post-treatment challenges include ensuring patient compliance and monitoring for drug toxicity.</p>
        <p>In the realm of treatment and management for multiple sclerosis, several disease-modifying therapies, as mentioned below, offer various mechanisms to address the underlying pathology.</p>
        <p><bold>Glatiramer acetate:</bold>&#x000a0;This is&#x000a0;a synthetic polypeptide mixture that may act as a ligand for major histocompatibility complex molecules, limiting their activation and promoting regulatory cell induction. This drug may also have neuroprotective and repair mechanisms.<xref ref-type="bibr" rid="article-25363.r35">[35]</xref>&#x000a0;Glatiramer acetate is administered subcutaneously and is generally well-tolerated; however, this drug is ineffective for progressive forms of multiple sclerosis.</p>
        <p><bold>Interferon-beta preparations:</bold>&#x000a0;These preparations act through multiple mechanisms, including modulation of T- and B-cell function, cytokine expression alteration, potential role in blood-brain barrier recovery, and reduction in matrix metalloproteinase expression. The administration&#x000a0;is subcutaneously or intramuscularly, and they may cause flu-like symptoms and possibly briefly worsen patients' neurological symptoms.</p>
        <p><bold>Natalizumab:</bold>&#x000a0;This drug is an intravenously (IV) administered humanized monoclonal antibody that blocks leukocyte adhesion to vascular endothelial cells, thereby inhibiting leukocyte migration into the CNS. Although generally well tolerated, natalizumab may cause mild headaches, and flushing may occur during IV administration.</p>
        <p><bold>Mitoxantrone:</bold>&#x000a0;This is an IV-administered&#x000a0;chemotherapeutic agent used to treat&#x000a0;multiple sclerosis due to its effects on DNA repair and RNA synthesis. A possible effect on cellular and humoral immunity may represent the therapy mechanism for multiple sclerosis.<xref ref-type="bibr" rid="article-25363.r36">[36]</xref>&#x000a0;However, its use is limited due to the various adverse effects that have been documented, including amenorrhea and alopecia.</p>
        <p><bold>Fingolimod:</bold>&#x000a0;This is&#x000a0;an orally administered drug with immunomodulatory effects, possibly relating to the inhibition of T-cell migration. However, possible adverse effects include lymphopenia, bradycardia, and hepatotoxicity, thereby necessitating careful monitoring.</p>
        <p>Patients with secondary progressive, progressive-relapsing, and primary progressive multiple sclerosis primarily experience neurodegenerative processes. Due to this, disease-modifying therapies show varying effectiveness, ranging from possible benefits to limited impact on disease progression. Typically, younger patients with a shorter duration of progression tend to benefit more from these therapies.</p>
        <p>
<bold>Guiding Principles for Acute Relapse Management</bold>
</p>
        <p>Several principles guide the treatment of acute relapses in multiple sclerosis,&#x000a0;including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Addressing possible underlying processes that could have triggered a relapse, such as an infection or metabolic derangement</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Providing symptomatic treatment based on specific neurological symptoms</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administering a short course of corticosteroids to assist in recovery</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Implementing rehabilitation programs involving physical and occupational therapy for comprehensive management</p>
          </list-item>
        </list>
        <p>Women of childbearing age should avoid certain medications due to their potential risks, as listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Teratogens: Teriflunomide, cladribine, siponimod, fingolimod, and ozanimod</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs associated with a higher risk of rebound symptoms upon discontinuation: Fingolimod,&#x000a0;siponimod, natalizumab, and ozanimod</p>
          </list-item>
        </list>
        <p>
<bold>Treatment of Acute Exacerbation of Multiple Sclerosis</bold>
</p>
        <p>Neurological symptoms may include increased disability, impairments in strength, cerebellar function, vision, or significant sensory disturbances.</p>
        <list list-type="bullet">
          <list-item>
            <p>IV or oral steroids may be prescribed by a physician, as described below, depending on a patient's conditions and symptoms.
<list list-type="bullet"><list-item><p>IV&#x000a0;methylprednisolone: This can be administered as&#x000a0;a 3- to 7-day course at 500 to 1000 mg daily, optionally followed by a short prednisone taper.<xref ref-type="bibr" rid="article-25363.r37">[37]</xref></p></list-item><list-item><p>Oral prednisone: This can be&#x000a0;administered at a dosage of 1250 mg/d of prednisone, with/without a short taper, and is an alternative to 3 to 7 days of oral methylprednisolone administered at 1000 mg/d.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Plasma exchange (PLEX) is recommended if a poor glucocorticoid response occurs.<xref ref-type="bibr" rid="article-25363.r38">[38]</xref>
<list list-type="bullet"><list-item><p>PLEX is administered daily or every other day for a total of 3 to 7 treatments.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of multiple sclerosis is extensive and can be categorized into&#x000a0;7 categories, as listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Other demyelinating or inflammatory CNS syndromes:
<list list-type="bullet"><list-item><p>Optic neuritis</p></list-item><list-item><p>Marburg disease</p></list-item><list-item><p>Acute disseminated encephalomyelitis</p></list-item><list-item><p>Devic neuromyelitis optical</p></list-item><list-item><p>Susac syndrome&#x000a0;<xref ref-type="bibr" rid="article-25363.r39">[39]</xref></p></list-item><list-item><p>Primary cerebral vasculitis and partial transverse myelitis</p></list-item><list-item><p>Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), a rare form of encephalomyelitis&#x000a0;typically affecting the&#x000a0;spinal cord, cerebellum, and brainstem&#x000a0;<xref ref-type="bibr" rid="article-25363.r40">[40]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>General inflammatory and autoimmune syndromes:
<list list-type="bullet"><list-item><p>Systemic lupus erythematosus</p></list-item><list-item><p>Wegener granulomatosis</p></list-item><list-item><p>Sarcoidosis</p></list-item><list-item><p>Antiphospholipid antibody syndrome</p></list-item><list-item><p>Behcet syndrome</p></list-item><list-item><p>Sj&#x000f6;gren syndrome</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infectious etiologies:
<list list-type="bullet"><list-item><p>Lyme disease</p></list-item><list-item><p>Syphilis</p></list-item><list-item><p>HIV</p></list-item><list-item><p>Herpes viruses</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vascular etiologies
<list list-type="bullet"><list-item><p>Migraine headaches</p></list-item><list-item><p>Dural arteriovenous fistula</p></list-item><list-item><p>Small vessel ischemia</p></list-item><list-item><p>Ischemic optic neuropathy (arteritic and nonarteritic)</p></list-item><list-item><p>Vascular malformations and emboli</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic causes:
<list list-type="bullet"><list-item><p>Vitamin deficiencies</p></list-item><list-item><p>Thyroid disease</p></list-item><list-item><p>Hereditary ataxias</p></list-item><list-item><p>Adult-onset leukodystrophy, such as adult-onset adrenoleukodystrophy</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Uncommon genetic etiologies:
<list list-type="bullet"><list-item><p>Mitochondrial cytopathy</p></list-item><list-item><p>Fabry disease</p></list-item><list-item><p>Alexander disease</p></list-item><list-item><p>Hereditary spastic paraplegia</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neoplastic causes include primary CNS malignancies, such as gliomas and meningiomas, or metastasis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis and severity of multiple sclerosis vary widely among patients,<xref ref-type="bibr" rid="article-25363.r41">[41]</xref>&#x000a0;and&#x000a0;the disease often exhibits mild symptoms early, which worsens over time.&#x000a0;</p>
        <p>Factors that suggest a worse prognosis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Male gender</p>
          </list-item>
          <list-item>
            <p>Progressive course</p>
          </list-item>
          <list-item>
            <p>Primarily pyramidal or cerebellar symptoms</p>
          </list-item>
          <list-item>
            <p>More frequent relapses</p>
          </list-item>
          <list-item>
            <p>Minimal recovery between relapses</p>
          </list-item>
          <list-item>
            <p>Multifocal onset</p>
          </list-item>
          <list-item>
            <p>High early relapse rate</p>
          </list-item>
          <list-item>
            <p>Large lesion load and brain atrophy on MRI</p>
          </list-item>
        </list>
        <p>Factors that suggest a favorable diagnosis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Female gender</p>
          </list-item>
          <list-item>
            <p>Relapsing course</p>
          </list-item>
          <list-item>
            <p>Mild relapses</p>
          </list-item>
          <list-item>
            <p>Good recovery between exacerbations</p>
          </list-item>
          <list-item>
            <p>Primarily sensory symptoms</p>
          </list-item>
          <list-item>
            <p>The long interval between the first and second relapses</p>
          </list-item>
          <list-item>
            <p>Low lesion load on MRI</p>
          </list-item>
          <list-item>
            <p>Presentation of optic neuritis</p>
          </list-item>
          <list-item>
            <p>Full recovery from exacerbations</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Long-term disability in multiple sclerosis results from incomplete recovery after each relapse, leading to an accumulation of symptoms over time.</p>
        <list list-type="bullet">
          <list-item>
            <p>Impaired mobility is observed in most long-term multiple sclerosis patients due to various factors. The reduction in mobility is multifactorial and possibly related to defective motor control and vestibular symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Brain stem lesions involving the oculomotor pathways can cause chronic diplopia, which may be managed with prisms or surgery.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic vertigo, another common issue, is a possible source of morbidity and may respond to medications such as meclizine, ondansetron, or diazepam.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic dysphagia due to bulbar dysfunction can lead to chronic aspiration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cerebellar tremors can potentially significantly affect a person's disability. While wrist weights may help manage tremors, potential superimposed weakness can preclude their use.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Urinary tract infections, considered long-term complications, can occur due to bladder dysfunction, which often necessitates consultation with urology specialists.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Constipation is the most frequent gastrointestinal complication, and this issue can be managed with patient education, increased fiber intake, and bulk-forming agents.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Erectile dysfunction is treated with oral phosphodiesterase-5 inhibitors if present.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cognitive impairment, mood disorders, and generalized fatigue are considered long-term sources of morbidity, and they are managed in various ways, often&#x000a0;involving subspecialty care.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Multiple sclerosis&#x000a0;is a&#x000a0;complex neurological disorder that leads to various neurological and non-neurological symptoms, disabilities, and complaints. A comprehensive team approach involves specialists from:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurology and neuro-ophthalmology</p>
          </list-item>
          <list-item>
            <p>Psychiatry and cognitive psychology</p>
          </list-item>
          <list-item>
            <p>Pain management</p>
          </list-item>
          <list-item>
            <p>Nursing and physician assistants</p>
          </list-item>
          <list-item>
            <p>Speech therapy</p>
          </list-item>
          <list-item>
            <p>Occupational therapy</p>
          </list-item>
          <list-item>
            <p>Social work</p>
          </list-item>
          <list-item>
            <p>Physical medicine and rehabilitation</p>
          </list-item>
          <list-item>
            <p>Urology (in the setting of genitourinary complications)</p>
          </list-item>
          <list-item>
            <p>Gastroenterology (in the setting of gastrointestinal complications)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25363.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Diagnosing multiple sclerosis can be challenging for patients, and clinicians play a crucial role in providing supportive counseling regarding the diagnosis. Predicting the disease course is complex, so clinicians must educate patients about the varied possibilities in disease progression. In addition, it is important to emphasize that many patients respond well to treatment and to explain the role of effective medications. Patients should also be directed to reputable online sources such as the Multiple Sclerosis International Federation and the National Multiple Sclerosis Society to learn more about their condition. Educating patients about the nature of relapses and long-term complications is also vital.</p>
        <p>Patients should be informed to contact their treating clinician promptly if they experience new neurological symptoms lasting more than 24 hours, as this may require corticosteroid administration. In addition, it is crucial to emphasize smoking cessation, take vitamin D supplementation, maintain a balanced diet, and adhere to lifestyle modifications. Patients should also receive counseling on the significance of adhering to disease-modifying therapy, considering the adverse effect profile of these medications.</p>
      </sec>
      <sec id="article-25363.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Multiple sclerosis is a complex disease process presenting with sensory, visual, weakness, coordination, and spasticity issues. Other health concerns include bladder and bowel dysfunction, depression, cognitive impairment, fatigue, sexual dysfunction, sleep disturbances, and vertigo. Due to its multisystem impact and reduced life expectancy, optimal management of multiple sclerosis necessitates an interprofessional healthcare team, including neurologists, pain specialists, therapists, nurse specialists, ophthalmologists, mental health nurses, gastroenterologists, urologists, nurses, and pharmacists, who can treat patients with multiple sclerosis.&#x000a0;</p>
      </sec>
      <sec id="article-25363.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25363&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25363">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/multiple-sclerosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25363">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25363/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25363">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25363.s17">
        <fig id="article-25363.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Optic Neuritis as an Indicator of Multiple Sclerosis. Optic neuritis can be visualized through fundoscopy, which may indicate the presence of multiple sclerosis. Contributed by S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="opticneu" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25363.s18">
        <fig id="article-25363.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Perivascular Plaques in Multiple Sclerosis as Seen in MRI. The MRI image reveals perivascular plaques in multiple sclerosis, with relatively decreased perivascular inflammation compared to active plaques. Contributed by S Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MS__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25363.s19">
        <fig id="article-25363.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Sagittal FLAIR Sequence&#x000a0;Demonstrating&#x000a0;a Hyperintense Lesion on MRI.&#x000a0;The image&#x000a0;shows a sagittal FLAIR sequence on MRI, highlighting a hyperintense lesion, a characteristic feature known as "Dawson fingers," frequently seen in multiple sclerosis. Contributed by D Tafti, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sag__t2__flair__ms" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25363.s20">
        <fig id="article-25363.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Axial FLAIR Sequence Demonstrating an Advanced Lesion Burden on MRI. The image shows an axial FLAIR sequence on MRI, highlighting an advanced lesion burden along the callososeptal interface, a characteristic finding in multiple sclerosis. Contributed by D Tafti, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ms__ax__t2__flair" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25363.s21">
        <fig id="article-25363.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Sagittal FLAIR MRI Brain Image Demonstrating Linear Hyperintense Lesions. The sagittal FLAIR image highlights linear hyperintense lesions perpendicular to the left lateral ventricle, a characteristic feature known as "Dawson fingers," commonly observed in multiple sclerosis. Contributed by D Tafti, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sag__t2__flair__ms3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25363.s22">
        <title>References</title>
        <ref id="article-25363.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noyes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weinstock-Guttman</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Impact of diagnosis and early treatment on the course of multiple sclerosis.</article-title>
            <source>Am J Manag Care</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>17 Suppl</issue>
            <fpage>s321</fpage>
            <page-range>s321-31</page-range>
            <pub-id pub-id-type="pmid">24494633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>University of California, San Francisco MS-EPIC Team:</collab>
              <name>
                <surname>Cree</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Gourraud</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Oksenberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bevan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crabtree-Hartman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Goodin</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Graves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Okuda</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>von B&#x000fc;dingen</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Zamvil</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caillier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ciocca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kanner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lincoln</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lizee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qualley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Santaniello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suleiman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panara</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Papinutto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Cutter</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Baranzini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Long-term evolution of multiple sclerosis disability in the treatment era.</article-title>
            <source>Ann Neurol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>499</fpage>
            <page-range>499-510</page-range>
            <pub-id pub-id-type="pmid">27464262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ntranos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lublin</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>90</fpage>
            <pub-id pub-id-type="pmid">27549391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsunoda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fujinami</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination.</article-title>
            <source>Springer Semin Immunopathol</source>
            <year>2002</year>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-25</page-range>
            <pub-id pub-id-type="pmid">12503060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blizzard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Otahal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van der Mei</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>82</volume>
            <issue>10</issue>
            <fpage>1132</fpage>
            <page-range>1132-41</page-range>
            <pub-id pub-id-type="pmid">21478203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sintzel</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Rametta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reder</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Vitamin D and Multiple Sclerosis: A Comprehensive Review.</article-title>
            <source>Neurol Ther</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-85</page-range>
            <pub-id pub-id-type="pmid">29243029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jakimovski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinstock-Guttman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zivadinov</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to <italic>in vivo</italic> imaging.</article-title>
            <source>Neural Regen Res</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>373</fpage>
            <page-range>373-386</page-range>
            <pub-id pub-id-type="pmid">30539801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westerlind</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ramanujam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uvehag</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kuja-Halkola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bottai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hillert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden.</article-title>
            <source>Brain</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>137</volume>
            <issue>Pt 3</issue>
            <fpage>770</fpage>
            <page-range>770-8</page-range>
            <pub-id pub-id-type="pmid">24441172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langer-Gould</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Waubant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children.</article-title>
            <source>Neurology</source>
            <year>2011</year>
            <month>Sep</month>
            <day>20</day>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1143</fpage>
            <page-range>1143-8</page-range>
            <pub-id pub-id-type="pmid">21865580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Dyment</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Risch</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sadovnick</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Ebers</surname>
                <given-names>GC</given-names>
              </name>
              <collab>Canadian Collaborative Study Group</collab>
            </person-group>
            <article-title>Twin concordance and sibling recurrence rates in multiple sclerosis.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2003</year>
            <month>Oct</month>
            <day>28</day>
            <volume>100</volume>
            <issue>22</issue>
            <fpage>12877</fpage>
            <page-range>12877-82</page-range>
            <pub-id pub-id-type="pmid">14569025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gorman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stankovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Broadley</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Modelling genetic susceptibility to multiple sclerosis with family data.</article-title>
            <source>Neuroepidemiology</source>
            <year>2013</year>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">23075677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alcina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abad-Grau</surname>
                <given-names>Mdel M</given-names>
              </name>
              <name>
                <surname>Fedetz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Izquierdo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ndagire</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Catal&#x000e1;-Rabasa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gay&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arnal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matesanz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations.</article-title>
            <source>PLoS One</source>
            <year>2012</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>e29819</fpage>
            <pub-id pub-id-type="pmid">22253788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mu&#x000f1;oz-Culla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Irizar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Otaegui</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The genetics of multiple sclerosis: review of current and emerging candidates.</article-title>
            <source>Appl Clin Genet</source>
            <year>2013</year>
            <volume>6</volume>
            <fpage>63</fpage>
            <page-range>63-73</page-range>
            <pub-id pub-id-type="pmid">24019748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tizaoui</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Multiple sclerosis genetics: Results from meta-analyses of candidate-gene association studies.</article-title>
            <source>Cytokine</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>106</volume>
            <fpage>154</fpage>
            <page-range>154-164</page-range>
            <pub-id pub-id-type="pmid">29103823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dilokthornsakul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Valuck</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Corboy</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Multiple sclerosis prevalence in the United States commercially insured population.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>86</volume>
            <issue>11</issue>
            <fpage>1014</fpage>
            <page-range>1014-21</page-range>
            <pub-id pub-id-type="pmid">26888980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zurawski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stankiewicz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Corrigendum to Multiple Sclerosis Re-Examined: Essential and Emerging Clinical Concepts.</article-title>
            <source>Am J Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>131</volume>
            <issue>12</issue>
            <fpage>1528</fpage>
            <pub-id pub-id-type="pmid">30509389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldenberg</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Multiple sclerosis review.</article-title>
            <source>P T</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-84</page-range>
            <pub-id pub-id-type="pmid">22605909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Didonna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oksenberg</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <chapter-title>The Genetics of Multiple Sclerosis</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Zagon</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <source>Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]</source>
            <publisher-name>Codon Publications</publisher-name>
            <publisher-loc>Brisbane (AU)</publisher-loc>
            <year>2017</year>
            <month>11</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">29261259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Culpepper</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Coffman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pulaski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maloni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mahan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Haselkorn</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kurtzke</surname>
                <given-names>JF</given-names>
              </name>
              <collab>Veterans Affairs Multiple Sclerosis Centres of Excellence Epidemiology Group</collab>
            </person-group>
            <article-title>The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.</article-title>
            <source>Brain</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>135</volume>
            <issue>Pt 6</issue>
            <fpage>1778</fpage>
            <page-range>1778-85</page-range>
            <pub-id pub-id-type="pmid">22628389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ascherio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Munger</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors.</article-title>
            <source>Ann Neurol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>504</fpage>
            <page-range>504-13</page-range>
            <pub-id pub-id-type="pmid">17492755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammond</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.</article-title>
            <source>Brain</source>
            <year>2000</year>
            <month>May</month>
            <volume>123 ( Pt 5)</volume>
            <fpage>968</fpage>
            <page-range>968-74</page-range>
            <pub-id pub-id-type="pmid">10775541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e4;usser-Kinzel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders.</article-title>
            <source>Front Immunol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>201</fpage>
            <pub-id pub-id-type="pmid">30800132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magliozzi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serafini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nicholas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Puopolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aloisi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.</article-title>
            <source>Brain</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>130</volume>
            <issue>Pt 4</issue>
            <fpage>1089</fpage>
            <page-range>1089-104</page-range>
            <pub-id pub-id-type="pmid">17438020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiggermann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Endmayr</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Torres</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ftberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kasprian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hametner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rauscher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Quantitative magnetic resonance imaging reflects different levels of histologically determined myelin densities in multiple sclerosis, including remyelination in inactive multiple sclerosis lesions.</article-title>
            <source>Brain Pathol</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>e13150</fpage>
            <pub-id pub-id-type="pmid">36720269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suda</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kartje</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Retrospective Cohort Study of Patient-Reported Urinary Tract Infection Signs and Symptoms Among Individuals With Neurogenic Bladder.</article-title>
            <source>Am J Phys Med Rehabil</source>
            <year>2023</year>
            <month>Aug</month>
            <day>01</day>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>663</fpage>
            <page-range>663-669</page-range>
            <pub-id pub-id-type="pmid">36927768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radecka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knyszy&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lubkowska</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Assessment of muscle fatigue in multiple sclerosis patients in electromyographic examinations.</article-title>
            <source>Eur J Phys Rehabil Med</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-163</page-range>
            <pub-id pub-id-type="pmid">36892519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leodori</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mancuso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maccarrone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tartaglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ianniello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Certo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baione</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ferrazzano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Malimpensa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Belvisi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pozzilli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berardelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neural bases of motor fatigue in multiple sclerosis: A multimodal approach using neuromuscular assessment and TMS-EEG.</article-title>
            <source>Neurobiol Dis</source>
            <year>2023</year>
            <month>May</month>
            <volume>180</volume>
            <fpage>106073</fpage>
            <pub-id pub-id-type="pmid">36906073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fedorko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wasserbauer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Markusova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Praksova</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adedokun</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Trinh</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Urinary tract infections in patients with multiple sclerosis and different methods of bladder evacuation.</article-title>
            <source>Actas Urol Esp (Engl Ed)</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>606</fpage>
            <page-range>606-612</page-range>
            <pub-id pub-id-type="pmid">36216764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Unusual symptoms and syndromes in multiple sclerosis.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4 Multiple Sclerosis</issue>
            <fpage>992</fpage>
            <page-range>992-1006</page-range>
            <pub-id pub-id-type="pmid">23917097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Teoli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rocha Cabrero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ghassemzadeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Lhermitte Sign</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">29630289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polman</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Reingold</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Banwell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clanet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Filippi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Havrdova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lublin</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sandberg-Wollheim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Waubant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weinshenker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wolinsky</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.</article-title>
            <source>Ann Neurol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-302</page-range>
            <pub-id pub-id-type="pmid">21387374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zipp</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fragoso</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Waubant</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>441</fpage>
            <page-range>441-445</page-range>
            <pub-id pub-id-type="pmid">31086264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bitsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuhlmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stadelmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lassmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lucchinetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ck</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions.</article-title>
            <source>Ann Neurol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>793</fpage>
            <page-range>793-6</page-range>
            <pub-id pub-id-type="pmid">11409432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramagopalan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giovannoni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>84</volume>
            <issue>8</issue>
            <fpage>909</fpage>
            <page-range>909-14</page-range>
            <pub-id pub-id-type="pmid">23431079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lalive</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Benkhoucha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hohlfeld</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zamvil</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.</article-title>
            <source>CNS Drugs</source>
            <year>2011</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>401</fpage>
            <page-range>401-14</page-range>
            <pub-id pub-id-type="pmid">21476611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wehner</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Gasper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shopp</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Draper</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Immunotoxicity profile of natalizumab.</article-title>
            <source>J Immunotoxicol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-29</page-range>
            <pub-id pub-id-type="pmid">19589098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of multiple sclerosis.</article-title>
            <source>BMJ</source>
            <year>2006</year>
            <month>Mar</month>
            <day>04</day>
            <volume>332</volume>
            <issue>7540</issue>
            <fpage>525</fpage>
            <page-range>525-7</page-range>
            <pub-id pub-id-type="pmid">16513709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arrambide</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iacobaeus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Derfuss</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vukusic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hemmer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brundin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tintore</surname>
                <given-names>M</given-names>
              </name>
              <collab>2018 ECTRIMS Focused Workshop Group</collab>
            </person-group>
            <article-title>Aggressive multiple sclerosis (2): Treatment.</article-title>
            <source>Mult Scler</source>
            <year>2020</year>
            <month>Jun</month>
            <day>12</day>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>1352458520924595</fpage>
            <pub-id pub-id-type="pmid">32530366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidal-Jordana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.</article-title>
            <source>Neuroimaging Clin N Am</source>
            <year>2017</year>
            <month>May</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-204</page-range>
            <pub-id pub-id-type="pmid">28391781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zalewski</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Tobin</surname>
                <given-names>WO</given-names>
              </name>
            </person-group>
            <article-title>CLIPPERS.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>65</fpage>
            <pub-id pub-id-type="pmid">28726127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25363.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergamaschi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in multiple sclerosis.</article-title>
            <source>Int Rev Neurobiol</source>
            <year>2007</year>
            <volume>79</volume>
            <fpage>423</fpage>
            <page-range>423-47</page-range>
            <pub-id pub-id-type="pmid">17531853</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
